Brief: Verrica Pharmaceuticals Reports Q1 2023 Financial Results
09/05/2023 13:30
May 9 (Reuters) - Verrica Pharmaceuticals Inc VRCA.O :
* VERRICA PHARMACEUTICALS REPORTS FIRST QUARTER 2023
FINANCIAL
RESULTS
* QTRLY NET LOS PER SHARE $0.15
* AS OF MARCH 31, 2023, VERRICA HAD AGGREGATE CASH AND CASH
EQUIVALENTS OF $60.0 MILLION
* VERRICA PHARMACEUTICALS - BELIEVES EXISTING CASH AND CASH
EQUIVALENTS WILL BE SUFFICIENT TO SUPPORT PLANNED OPERATIONS
INTO Q1 OF 2024
* Q1 EARNINGS PER SHARE VIEW $-0.19 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX578vQ2
Further company coverage: VRCA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Verrica Pharmaceuticals
See all newsVerrica Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Verrica Pharma reports wider-than-expected Q2 adj loss per share
Verrica Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Verrica Pharmaceuticals Q1 revenue rises on YCANTH demand
Brief: Verrica Pharmaceuticals Announces Upcoming Presentation Of Phase 2 Data